Summary

for people ages 18 years and up (full criteria)
at Irvine, California
study started
estimated completion
Neal Hermanowicz, MD

Description

Summary

The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglyerides (fats), as a treatment for Huntington's disease (HD). Subjects who meet the entry criteria will be randomized (3:1) to either 145mg of fenofibrate or placebo.

Official Title

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

Keywords

Huntington Disease Fenofibrate

Eligibility

You can join if…

Open to people ages 18 years and up

  • An adult of either sex, ages 25-85 inclusive,
  • Have proficiency with written and spoken English and corrected vision or hearing to complete the cognitive testing,
  • Are able to give informed consent,
  • Have good overall health status with no known problems anticipated over the course of the trial,
  • Have a diagnosis of HD supported by positive gene test within the past 6 months.

You CAN'T join if...

  • Other major neurological disease [e.g., multiple sclerosis, parkinson's disease, cortical stroke, etc]
  • Clinically significant hepatic or renal disease,
  • Current or recent (< 1 month) use of dopamine blocking agents such as tetrabenazine, anticonvulsants, neuroleptics, HAART, antiemetics, and antipsychotics for any reason,
  • Current use of Warfarin (Coumadin). Enrollment in another investigational drug study within the prior three months.

Location

  • University of California, Irvine
    Irvine California 92697 United States

Lead Scientist

  • Neal Hermanowicz, MD
    Health Sciences Professor, Neurology. Authored (or co-authored) 25 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT03515213
Phase
Phase 2
Study Type
Interventional
Last Updated